Edition:
United Kingdom

Co-Diagnostics Inc (CODX.OQ)

CODX.OQ on NASDAQ Stock Exchange Capital Market

1.09USD
16 Sep 2019
Change (% chg)

$0.02 (+1.87%)
Prev Close
$1.07
Open
$1.10
Day's High
$1.10
Day's Low
$1.06
Volume
2,444
Avg. Vol
174,691
52-wk High
$3.77
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Co-Diagnostics Says All Debt Incurred In 2018 Was Eliminated In Sale Of $3 Mln Of Preferred Shares In January 2019
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. REPORTS 2018 YEAR-END FINANCIAL RESULTS AND PROGRESS UPDATES.CO-DIAGNOSTICS - ALL DEBT INCURRED IN 2018 WAS ELIMINATED IN SALE OF $3 MILLION OF PREFERRED SHARES IN JANUARY 2019.  Full Article

CVI Investments Reports A Passive Stake Of 7.8 Pct In Co-Diagnostics As Of Jan 31, 2019
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Co-Diagnostics Inc ::CVI INVESTMENTS REPORTS A PASSIVE STAKE OF 7.8 PERCENT IN CO-DIAGNOSTICS INC AS OF JAN 31, 2019 - SEC FILING.  Full Article

Co-Diagnostics Announces Elimination Of Debt, Additional Capital Infusion
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. ANNOUNCES ELIMINATION OF DEBT, ADDITIONAL CAPITAL INFUSION.CO-DIAGNOSTICS INC - SALE OF $3 MILLION OF PREFERRED SHARES, CONVERTIBLE TO COMMON STOCK AT A FIXED PRICE OF $1.20 PER SHARE.CO-DIAGNOSTICS INC - TRANSACTION CONSISTED OF NEGOTIATING CONVERSION OF A $2 MILLION NOTE TO PREFERRED STOCK.CO-DIAGNOSTICS INC - TRANSACTION INCLUDED $3 MILLION OF PREFERRED SHARES, AND ELIMINATION OF $2 MILLION OF DEBT.  Full Article

Co-Diagnostics Inc And LGC, Biosearch Technologies Sign License Agreement For Coprimer Technology
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. AND LGC, BIOSEARCH TECHNOLOGIES SIGN LICENSE AGREEMENT FOR COPRIMER TECHNOLOGY.CO-DIAGNOSTICS INC - CO-DIAGNOSTICS AGREES TO LICENSE COPRIMERS FOR USE IN AGRICULTURAL APPLICATIONS.  Full Article

Co-Diagnostics Receives CE Mark For Zika Screening Test
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. RECEIVES CE MARK FOR ZIKA SCREENING TEST.CO-DIAGNOSTICS INC - CO'S LOGIX SMART ZIKA TEST TO BE AVAILABLE FOR PURCHASE WITH CE MARK.  Full Article

Co-Diagnostics Receives CE Mark For Tuberculosis Test Kit
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS RECEIVES CE MARK FOR TUBERCULOSIS TEST KIT.  Full Article

Co-Diagnostics Completes Submission Of CE Mark Registration For Tuberculosis Screening Test
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS COMPLETES SUBMISSION OF CE MARK REGISTRATION FOR TUBERCULOSIS SCREENING TEST.CO-DIAGNOSTICS INC - COMPANY'S LOGIX SMART MTB TEST TO BE AVAILABLE FOR PURCHASE WITH CE MARK IN AUGUST 2018.  Full Article

Co-Diagnostics, Inc. Announces Advancement Of Co-Primers™ Technology In Multiplex SNP Genotyping
Tuesday, 5 Jun 2018 

Co-Diagnostics Inc ::CO-DIAGNOSTICS, INC. ANNOUNCES ADVANCEMENT OF CO-PRIMERS™ TECHNOLOGY IN MULTIPLEX SNP GENOTYPING.CO-DIAGNOSTICS INC - PROOF OF CONCEPT STUDY SUCCESSFUL IN DEMONSTRATING POTENTIAL SNP MULTIPLEXING APPLICATIONS.  Full Article

Co-Diagnostics Enters Into Lease For Upgraded Laboratory Facility In Salt Lake City
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Co-Diagnostics Inc ::CO-DIAGNOSTICS - ENTERS INTO LEASE FOR BIOLOGICAL SAFETY LEVEL 2 LABORATORY FACILITY IN SALT LAKE CITY, UTAH.CO-DIAGNOSTICS INC - LABORATORY WILL MEET CGMP REQUIREMENTS OF FDA.  Full Article

Co-Diagnostics Inc says qtrly loss per share $‍0.33​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Co-Diagnostics Inc -:Co-Diagnostics, Inc. Reports Q3 financial results and updates corporate developments.Co-Diagnostics Inc - qtrly loss per share $‍0.33​.  Full Article